Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p17
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 17/31)
Character Range: 53864–57914

Part 2, after entry for Sterculia with frangula bark in the form Granules 620 mg-80 mg per g, 500 g [Maximum Quantity: 1; Number of Repeats: 3]
                           insert:
Triglycerides, medium chain            Oral liquid 225 mL, 15 (K.Quik)                        Oral     K.Quik                    VF  MP NP  C6147 C6191                           2    5  1
Triglycerides - medium chain, formula  Sachets containing oral powder 16 g, 30 (MCT Pro-Cal)  Oral     MCT Pro-Cal               VF  MP NP  C6136 C6156 C6165 C6173 C6192         4    5  1
Varenicline                            Tablet 1 mg (as tartrate) (s19A)                       Oral     APO-Varenicline (Canada)  XT  MP NP  C6885 C7483                    P6885  56   2  56
                                                                                                                                     MP NP  C6885 C7483                    P7483  112  0  56

     [106]           Schedule 4, Part 1, entry for Acalabrutinib
         (a)           insert in the column headed "Purposes Code" for the entry for Circumstances Code "C12495": P12495
         (b)           insert in the column headed "Purposes Code" for the entry for Circumstances Code "C12500": P12500
         (c)           omit:
   C14344        Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)                                                                                                                                                                 Compliance with Authority Required procedures
                 Treatment of relapsed/refractory disease
                 The condition must have relapsed or be refractory to at least one prior therapy; AND
                 The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition; AND
                 The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
                 Patient must not be undergoing retreatment with this drug where prior, active treatment of CLL/SLL with this same drug was unable to prevent disease progression; AND
                 Patient must be undergoing treatment through this treatment phase listing for the first time; OR
                 Patient must be undergoing treatment through this treatment phase listing on a subsequent occasion, with disease progression being absent.

         (d)           insert in numerical order after existing text:
   C14788  P14788     Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)                                                                                                                                                                                      Compliance with Authority Required procedures
                      Treatment of relapsed/refractory disease
                      The condition must have relapsed or be refractory to at least one prior therapy; AND
                      The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition; AND
                      The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
                      Patient must not be undergoing retreatment (second/subsequent treatment course) with this drug where prior treatment of CLL/SLL with this same drug was unable to prevent disease progression; AND
                      Patient must be undergoing treatment through this treatment phase listing for the first time (initial treatment); OR
                      Patient must be undergoing continuing treatment through this treatment phase listing, with disease progression being absent.
   C14795  P14795     Chronic lymphocytic leukaemia (CLL) or small